Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 1, 1997, Pages 44-51

  Crespo, Nelson ^a   Alvarez, Rafael ^a   Más, Rosa ^a   Illnait, José ^a   Fernández, Lilia ^a   Fernández, Julio César ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

hypercholesterolemia; non insulin dependent diabetes mellitus; policosanol

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031018756     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80077-X     Document Type: Article

References (38)

1. Steiner G. Diabetes and atherosclerosis. An overview. Diabetes. 1981;30:1-7.
2. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis. 1984;26:373-412.
3. Castelli WP. Epidemiology of coronary heart disease: The Framingham study. Am J Med. 1984;76:3-12.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 1984;251:351-373.
5. Barret-Connor E, Grundy SM, Holdbroock MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657-663.
6. Laakso M, Voutilainen E, Sarlund H, et al. Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetes. Atherosclerosis. 1985;56:271-281.
7. Briones ER, Mao SJT, Palumbo PJ, et al. Analysis of plasma lipids and apolipoproteins in insulin-dependent and non-insulin-dependent diabetics. Metabolism. 1984;33:42-49.
8. Gotto AM, Assman G, Carmena R, et al. Population subsets: Management of patients with diabetes mellitus. In: The ILIB Lipid Handbook for Clinical Practice. Washington, DC: International Lipid Information Bureau; 1995:1-195.
9. Witztum JL, Mahoney LM, Ranks MJ, et al. Non-enzymatic glycosylation of LDL alters its biologic activity. Diabetes. 1982;31:283-291.
10. Lopes-Virella MF, Klein RL, Lyons TJ, et al. Glycosylation of low density lipoproteins enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988;37:550-557.
11. WHO. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: The World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia. 1985;28(Suppl):615-640.
12. Abbate SL, Brunzell D. Pathophysiology of hyperlipidemia in diabetes mellitus. J Cardiovasc Pharmacol. 1990;16:S1-S7.
13. Castano G, Zardoya R, Illnait J, et al. Efectos del tratamiento con PPG (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM. 1991;5:21-30.
14. Pons P, Más R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res. 1992;52:507-513.
15. Pons P, Jiménez A, Rodríguez M, et al. Effects of policosanol in elderly hypercholesterolemic patients. Curr Ther Res. 1993;53:265-269.
16. Aneiros E, Calderón B, Más R, et al. Effect of policosanol successive dose increases on lipid profile and tolerability to treatment. Curr Ther Res. 1993;54:304-312.
17. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J Clin Pharmacol Res. 1994;14:27-33.
18. Pons P, Rodriguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
19. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
20. Castaño G, Mãs R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
21. Canetti M, Morera M, Illnait J, et al. One year study on the effect of policosanol (5 mg twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 1995;12:245-254.
22. Canetti M, Morera M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res. 1995;15:159-165.
23. Castaño G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res. 1996;57:691-699.
24. Menéndez R, Fraga V, Sotolongo V, et al. Efecto de la administración oral del policosanol sobre el metabolismo lipídico de ratas normocolesterolémicas. Rev Mex Cien Farmac. 1993;24:16-18.
25. Menéndez R, Fernández I, del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
26. Alemán CL, Rodeiro I, Noa M, et al. Acute subchronic and chronic toxicity of policosanol in rats. Presented at the Sixth International Congress of Toxicology, Rome, Italy; June 28-July 3, 1992; Abstract 248.
27. Alemán CL, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
28. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutagen. 1994;14:239-249.
29. Alemán CL, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: An 18 month study. Food Chem Toxicol. 1995;33:573-578.
30. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
31. Rodriguez C, Mesa R, Más R, et al. Effect of policosanol chronically administered in male monkeys. (Macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
32. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen. 1994;14:107-113.
33. Torres O, Illnait J, Más R, et al. Treatment of hypercholesterolemia in non-insulin-dependent diabetes mellitus with policosanol. Diabetes Care. 1993;18:393-397.
34. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
35. Illingworth DR. An overview of lipid-lowering drugs. Drugs. 1988;36:63-71.
36. Yoshino G, Kasumi T, Iwai M, et al. Tratamiento a largo plazo de la hipercolesterolemia en diabéticos no insulino dependientes con pravastatina. Atherosclerosis. 1989;75:67-72.
37. Garg A, Scatt M, Grundy MD. Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin. Am J Cardiol. 1988;62:44J-49J.
38. Golberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1990;66:16B-21B.